Milestone Pharmaceuticals Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

MIST$0.66-10.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Loss

Condensed Consolidated Statements of Loss** (Unaudited)**

(in thousands of US dollars, except share and per share data)


· · · · ·
· · Three months ended September 30, · · Nine months ended September 30, ·
· 2025 · 2024 · 2025 · 2024 ·

Revenue	$—	$—	$—	$—

Operating expenses
Research and development, net of tax credits	3,940	3,963	12,587	10,417
General and administrative	3,263	3,742	12,189	12,741
Commercial	4,626	1,911	20,107	6,596

Loss from operations	(11,829)	(9,616)	(44,883)	(29,754)

Interest income	874	1,080	2,087	3,260
Interest expense	(967)	(903)	(2,853)	(2,662)

Net loss and comprehensive loss	$(11,922)	$(9,439)	$(45,649)	$(29,156)

Weighted average number of shares and pre-funded warrants outstanding, basic and diluted	96,494,588	66,190,302	76,497,361	60,856,495

Net loss per share, basic and diluted	$(0.12)	$(0.14)	$(0.60)	$(0.48)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.